ArticlePakistan journal of medical sciences2025
Exploring Retinopathy of Prematurity: Insights from the First USAID-Funded Screening Program in KPK, Pakistan.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate incidence, demographics and risk factor associated with Retinopathy of prematurity. Methods: It was multi-centered prospective cross sectional study. Department of Ophthalmology at Khyber Teaching Hospital conducted this study, from February 2022 to September 2023 in collaboration with three teaching hospitals based in Peshawar. It was funded by United States Agency for International Development (USAID) with Grant No. CBP051. Infants born at ≤ 35 weeks, or birth weight ≤ 2kg, or admitted to Neonatal Intensive Care Unit (NICU) for ≥ three days were included. Screening was conducted at ≥3-4 weeks after birth or 31 completed weeks post-conception, whichever came first. Endpoint for follow-up was complete vascularization of temporal retina. Results: It included 622 of 840 screened infants, with 98(15.8%) ROP cases. Among diagnosed, 56.1% were males, 66.3% born between 26-30 weeks, and 63.3% with birth weight between 0.6-1.5 kg. 62.2% were at 1-4 months of age, 98.9% had screening weight range 1-3 kg, 99% received postnatal oxygen therapy, and 24.5% had neonatal diseases. In multivariate analysis, risk factors including gestational age (AOR 0.793, 95% CI 0.69-0.90), postnatal oxygen therapy (AOR 40, 95% CI 1.9-817), duration of postnatal oxygen therapy (AOR 1.05, 95% CI 1.02-1.07), birth weight (AOR 0.3, 95% CI 0.125-0.725), blood transfusion (AOR 349, 95% CI 17.7-9601), and neonatal diseases (AOR 2.4, 95% CI 1.2-4.8) were found significant. Conclusions: Gestational age, postnatal oxygen therapy and neonatal disease are significant factors associated with ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.